Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?

被引：14
作者：
Hurwitz, Herbert I. [1 ]
Lyman, Gary H. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC 27708 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 06期
关键词：
PROGRESSION-FREE SURVIVAL; 1ST-LINE TREATMENT; CLINICAL-TRIALS; PHASE-III; CHEMOTHERAPY; FLUOROURACIL; METAANALYSIS; LEUCOVORIN;
D O I：
10.1200/JCO.2011.40.7031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：580 / 581
页数：2
相关论文
共 18 条
  • [1] [Anonymous], J CLIN ONCOL S4
  • [2] Bekaii-Saab TS, 2008, J CLIN ONCOL S15, V26, p644s
  • [3] Progression-free survival is a surrogate for survival in advanced colorectal cancer
    Buyse, Marc
    Burzykowski, Tomasz
    Carroll, Kevin
    Michiels, Stefan
    Sargent, Daniel J.
    Miller, Langdon L.
    Elfring, Gary L.
    Pignon, Jean-Pierre
    Piedbois, Pascal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5218 - 5224
  • [4] A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer
    Cao, Yunfei
    Tan, Aihua
    Gao, Feng
    Liu, Lidan
    Liao, Cun
    Mo, Zengnan
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (06) : 677 - 685
  • [5] Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy-An Aide et Recherche en Cancerologie Digestive Group Study
    Chibaudel, Benoist
    Bonnetain, Franck
    Shi, Qian
    Buyse, Marc
    Tournigand, Christophe
    Sargent, Daniel J.
    Allegra, Carmen J.
    Goldberg, Richard M.
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4199 - 4204
  • [6] Issues in Using Progression-Free Survival When Evaluating Oncology Products
    Fleming, Thomas R.
    Rothmann, Mark D.
    Lu, Hong Laura
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2874 - 2880
  • [7] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
    Grothey, Axel
    Sugrue, Mary M.
    Purdie, David M.
    Dong, Wei
    Sargent, Daniel
    Hedrick, Eric
    Kozloff, Mark
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5326 - 5334
  • [8] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
  • [9] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Kabbinavar, F
    Hurwitz, HI
    Fehrenbacher, L
    Meropol, NJ
    Novotny, WF
    Lieberman, G
    Griffing, S
    Bergsland, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65
  • [10] Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
    Kabbinavar, Fairooz F.
    Hurwitz, Herbert I.
    Yi, Jing
    Sarkar, Somnath
    Rosen, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 199 - 205
12